Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
RANI– Announced strategic research collaboration with Chugai for two undisclosed molecules –
August 7, 2025Earnings
Read more →Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
RANIMay 19, 2025
Read more →Oppenheimer Maintains Outperform on Rani Therapeutics Hldgs, Lowers Price Target to $4
RANIMay 16, 2025
Read more →Rani Therapeutics Hldgs Q1 EPS $(0.22) Misses $(0.21) Estimate, Sales $172.00K
RANIMay 13, 2025
Read more →Rani Therapeutics Says On May 1, 2025 It Received A Letter Of Non-Complaisance From Nasdaq
RANIMay 7, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target
RANIApril 3, 2025
Read more →Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate
RANIMarch 31, 2025
Read more →An Overview of Rani Therapeutics Hldgs's Earnings
RANIMarch 28, 2025
Read more →Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist
RANIMarch 26, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target
RANINovember 19, 2024
Read more →Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate
RANINovember 14, 2024
Read more →